<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Niacin (vitamin B3): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Niacin (vitamin B3): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Niacin (vitamin B3): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11399" href="/d/html/11399.html" rel="external">see "Niacin (vitamin B3): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="12642" href="/d/html/12642.html" rel="external">see "Niacin (vitamin B3): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F200983"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Niacin-50 [OTC] [DSC];</li>
<li>Niacor;</li>
<li>Niaspan [DSC];</li>
<li>Slo-Niacin [OTC];</li>
<li>True Vitamin B3 [OTC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F201008"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antilipemic Agent, Miscellaneous;</li>
<li>
                        Vitamin, Water Soluble</li></ul></div>
<div class="block doa drugH1Div" id="F200986"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Formulations of niacin (regular release versus extended release) are not interchangeable.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="81863c66-ac4f-45ff-b638-ded564c6efe2">Dietary supplement</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary supplement (OTC labeling):</b>
<b>Oral:</b> 50 mg twice daily or 100 to 250 mg once daily. <b>Note:</b> Many over-the-counter formulations exist.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f71eb8fe-d05e-4ef8-91ed-8e7a986cef46">Dyslipidemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dyslipidemia:</b>
<b>Oral: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Niacin is no longer recommended, except in specific clinical situations (eg, high triglyceride levels [&gt;500 mg/dL], if not able to achieve desired response, or intolerance to other therapies) (ACC [Lloyd-Jones 2017]; Boden 2014; Garg 2017; Landray 2014; Wierzbicki 2014).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Regular release formulation (Niacor):</i> Initial: 250 mg once daily (with evening meal); increase frequency and/or dose every 4 to 7 days to desired response or first-level therapeutic dose (1.5 to 2 g daily in 2 to 3 divided doses); after 2 months, may increase at 2- to 4-week intervals to 3 g daily in 3 divided doses (maximum dose: 6 g daily in 3 divided doses). <b>Note:</b> Many over-the-counter formulations exist.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Sustained release (or controlled release) formulations:</i>
<b>Note:</b> Several over-the-counter formulations exist. Slo-Niacin: Usual dosage is 250 to 750 mg once daily, taken morning or evening, or as directed. Before using more than 500 mg daily, patient should consult health care provider.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Extended release formulation (Niaspan):</i> Initial: 500 mg at bedtime for 4 weeks, then 1 g at bedtime for 4 weeks; adjust dose to response and tolerance; may increase daily dose every 4 weeks by not more than 500 mg daily to a maximum of 2 g daily. Recommended maintenance dose: 1,000 to 2,000 mg at bedtime.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="7efa4463-d284-4c07-8f65-a72893073b55">Pellagra</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pellagra (off-label use):</b>
<b>Oral:</b>
<i>Regular release formulation:</i> 50 to 100 mg 3 to 4 times daily; maximum: 500 mg daily (Prousky 2003; Delgado-Sanchez 2008; DesGroseilliers 1976; Oldham 2012). Some experts prefer niacinamide for treatment due to more favorable side effect profile (Hegyi 2004; Jen 2010).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy: </b>Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991221"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block doha drugH1Div" id="F50988437"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Contraindicated in patients with significant or unexplained hepatic dysfunction, active liver disease or unexplained persistent transaminase elevations.</p></div>
<div class="block dot drugH1Div" id="F5943170"><span class="drugH1">Dosing: Adjustment for Toxicity: Adult</span>
<p style="text-indent:0em;text-align:justify;display:inline">Hepatic toxicity: Transaminases rise ≥3 times ULN, either persistent or if symptoms of nausea, fever, and/or malaise occur: Discontinue therapy.</p></div>
<div class="block doe drugH1Div" id="F200987"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F200999"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="12642" href="/d/html/12642.html" rel="external">see "Niacin (vitamin B3): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Formulations of niacin (regular release [crystalline] versus extended release) are not interchangeable.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="f71eb8fe-d05e-4ef8-91ed-8e7a986cef46">Dyslipidemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dyslipidemia: </b>Very limited data available (Miller 2015): <b>Note:</b> Niacin (nicotinic acid) is rarely used in pediatric patients for treatment of dyslipidemias and is not considered a primary agent nor a routine secondary, adjunctive agent for dyslipidemia management in pediatric patients (AAP [Daniels 2008]; AHA [McCrindle 2007]; NHLBI 2011)</p>
<p style="text-indent:-2em;margin-left:4em;">Children ≥10 years and Adolescents (Miller 2015; NHLBI 2011): Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">Regular release: Initial: 100 to 250 mg/day in 3 divided doses with meals; maximum initial daily dose: 10 mg/kg/<b>day</b>; increase weekly by 100 mg/day or increase every 2 to 3 weeks by 250 mg/day as tolerated; evaluate efficacy and adverse effects with laboratory tests at 20 mg/kg/day or 1,000 mg/day (whichever is less); continue to increase if needed and as tolerated; re-evaluate at each 500 mg increment; daily doses up to 2,250 mg/<b>day</b> have been used (Colletti 1993)</p>
<p style="text-indent:-2em;margin-left:6em;">Sustained release: Reported range: 500 to 1,500 mg/day; initiate at a low dose administered once daily (based on experience in adults); reported initial daily dose has not exceeded 10 mg/kg/<b>day;</b> titrate every 3 to 4 weeks (in adults, doses are titrated every 4 weeks) (AHA [McCrindle 2007]; Colletti 1993)</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6f14c539-7729-4d2b-93d8-926f06754e6c">Pellagra; treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Pellagra; treatment</b>: Children and Adolescents: Oral: Regular release: 50 to 300 mg/day in divided doses 3 times daily; usual treatment duration is 3 to 4 weeks (Kliegman 2016; WHO 2000)</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosing adjustment for toxicity: </b>Children ≥10 years and Adolescents: In a trial of pediatric patients, discontinuation of niacin therapy was reported for hepatotoxicity (eg, transaminases increases, either persistent or if symptoms of nausea, fever, and/or malaise), headache, abdominal pain and/or severe flushing (Colletti 1993)</p></div>
<div class="block dorp drugH1Div" id="F51130783"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">There are no dosage adjustments provided in the manufacturer's labeling (has not been studied); use with caution.</p></div>
<div class="block dohp drugH1Div" id="F51130784"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">All patients: There are no dosage adjustments provided in the manufacturer's labeling (has not been studied). Contraindicated in patients with significant or unexplained hepatic dysfunction, active liver disease, or unexplained persistent transaminase elevations.</p></div>
<div class="block adr drugH1Div" id="F200955"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Atrial fibrillation, cardiac arrhythmia, edema, flushing, hypotension, orthostatic hypotension, palpitations, tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills, dizziness, headache, insomnia, migraine, myasthenia, nervousness, pain, paresthesia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acanthosis nigricans, burning sensation of skin, diaphoresis, hyperpigmentation, maculopapular rash, pruritus, skin discoloration, skin rash, urticaria, xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Decreased glucose tolerance, decreased serum phosphate, gout, hyperuricemia, increased amylase, increased lactate dehydrogenase</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain, diarrhea, dyspepsia, eructation, flatulence, nausea, peptic ulcer, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Decreased platelet count, prolonged prothrombin time</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Hepatitis, increased serum bilirubin, increased serum transaminases (dose-related), jaundice,</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase, leg cramps, myalgia, myopathy (with concurrent HMG-CoA reductase inhibitor), weakness</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Blurred vision, cystoid macular edema, toxic amblyopia</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough, dyspnea</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Hepatic necrosis, hypersensitivity reaction (includes anaphylaxis, angioedema, laryngismus, vesiculobullous rash), rhabdomyolysis (with concurrent HMG-CoA reductase inhibitor), syncope</p></div>
<div class="block coi drugH1Div" id="F200968"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to niacin, niacinamide, or any component of the formulation; active hepatic disease or significant or unexplained persistent elevations in hepatic transaminases; active peptic ulcer; arterial hemorrhage</p></div>
<div class="block war drugH1Div" id="F200952"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Flushing/pruritus: Flushing and pruritus are common adverse effects of niacin; may be attenuated with a gradual increase in dose, administering with food, avoidance of concurrent ingestion of ethanol, hot or spicy foods/liquids, and/or by taking aspirin 30 minutes before dosing. May also use other NSAIDs according to the manufacturer. Flushing associated with extended-release preparation is significantly reduced (Guyton 2007). For immediate-release preparations, may administer in 2 to 3 divided doses to reduce the frequency and severity of flushing/pruritus. Consider discontinuation if persistent severe cutaneous symptoms occur during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• GI effects: May cause GI distress, vomiting, diarrhea, or aggravate peptic ulcer; GI distress may be attenuated with a gradual increase in dose and administration with food. Use is contraindicated in patients with active peptic ulcer disease; use with caution in patients with a past history of peptic ulcer. Consider discontinuation if unexplained abdominal pain/weight loss or other GI symptoms occur during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hematologic effects: Dose-related reductions in platelet count and increases of prothrombin time may occur.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatotoxicity: Cases of severe hepatotoxicity, including fulminant hepatic necrosis, have occurred when immediate-release (crystalline) niacin products have been substituted with sustained-release (modified-release, timed-release) niacin products at equivalent doses. Patients should be initiated with low doses (eg, niacin extended-release 500 mg at bedtime) with titration to achieve desired response. Liver function tests should be monitored in all patients receiving lipid-lowering doses of niacin. Discontinue use if hepatic transaminase levels rise, particularly to 3 x ULN and are persistent, or if they are associated with symptoms of nausea, fever, and/or malaise.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypophosphatemia: Has been associated with small but statistically significant dose-related reductions in phosphorus levels. Monitor phosphorus levels periodically in patients at risk for hypophosphatemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular disease: Use with caution in patients with unstable angina or in the acute phase of an MI. In patients with preexisting coronary artery disease, the incidence of atrial fibrillation was observed more frequently in those receiving immediate-release (crystalline) niacin as compared to placebo (Coronary Drug Project Research Group 1975). Consider discontinuation if new-onset atrial fibrillation occurs during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use is associated with new-onset diabetes or worsening glucose tolerance in patients with preexisting diabetes (Garg 2017; Goldie 2016). Use with caution in patients with diabetes. Monitor glucose; adjustment of diet and/or hypoglycemic therapy may be necessary. Consider discontinuation if persistent hyperglycemia occurs during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Gout: May be associated with hyperuricemia. Use with caution in patients predisposed to gout. Consider discontinuation if acute gout occurs during therapy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution in patients with a past history of hepatic impairment; monitor liver function tests. Contraindicated with active liver disease or unexplained persistent transaminase elevation.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution in patients with renal impairment.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Product interchangeability: Formulations of niacin (immediate-release versus extended-release) are not interchangeable (bioavailability varies): cases of severe hepatotoxicity, including fulminant hepatic necrosis, have occurred in patients who have substituted niacin products at equivalent doses.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Alcohol use: Use with caution in patients who consume large amounts of ethanol due to the increased risk of liver dysfunction.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878563"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In pediatric patients, a high incidence of reversible adverse effects has been observed; in a dyslipidemia trial (n=21, age range: 4 to 14 years), flushing was most common (71%); increased liver enzymes were observed in 29% of patients; in the trial, dosage form (crystalline or sustained release) did not affect adverse effect incidence (Colletti 1993).</p></div>
<div class="block foc drugH1Div" id="F200962"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Extended Release, Oral [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg [DSC], 500 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Powder, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic:  (100 g, 500 g, 1000 g)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Niacin-50: 50 mg [DSC] [starch free, sugar free, wheat free]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Niacor: 500 mg [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">True Vitamin B3: 50 mg, 100 mg, 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 50 mg, 100 mg, 250 mg, 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg [DSC], 500 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Niaspan: 500 mg [DSC] [contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Niaspan: 750 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Niaspan: 1000 mg [DSC] [contains fd&amp;c yellow #6(sunset yellow)alumin lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Slo-Niacin: 250 mg [scored; contains fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Slo-Niacin: 500 mg [contains fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Slo-Niacin: 500 mg, 750 mg [scored; contains fd&amp;c red #40 (allura red ac dye)]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 500 mg, 750 mg, 1000 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Extended Release, Oral [preservative free]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 250 mg, 500 mg, 1000 mg</p></div>
<div class="block geq drugH1Div" id="F200948"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F200970"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule Extended Release</b> (Niacin ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $0.05 - $0.09</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Niacin ER (Antihyperlipidemic) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $2.50 - $5.22</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $3.39 - $6.04</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $4.71 - $9.22</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Niacin ER Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $0.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.06</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1000 mg (per each): $0.07</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, controlled release</b> (Slo-Niacin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $0.11</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.17</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">750 mg (per each): $0.20</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Niacin (Antihyperlipidemic) Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $11.54 - $11.82</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Niacin Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $0.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">100 mg (per each): $0.03</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">250 mg (per each): $0.05</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $0.03 - $0.06</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Niacor Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">500 mg (per each): $4.73</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867675"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Solution, Injection: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 100 mg/mL ([DSC])</p></div>
<div class="block adm drugH1Div" id="F200965"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">Administer with food. To attenuate flushing symptoms, may premedicate with aspirin 30 minutes before dose; avoid ingestion of alcohol, hot or spicy foods/liquids concurrently with niacin. May also use other nonsteroidal anti-inflammatory drugs to prevent flushing according to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:2em;">Niaspan: Administer at bedtime after a low-fat snack. Two of the 500 mg and one of the 1,000 mg tablet strengths are interchangeable, but three of the 500 mg and two of the 750 mg tablet strengths are not interchangeable. When switching from IR tablet, initiate Niaspan with the recommended titration schedule. If therapy is interrupted for an extended period, dose should be retitrated.</p>
<p style="text-indent:-2em;margin-left:2em;">Long-acting forms should not be crushed, broken, or chewed. Slo-Niacin may be broken along the score line. Do not substitute long-acting forms for immediate release ones.</p>
<p style="text-indent:-2em;margin-left:2em;">Bariatric surgery: Capsule and tablet, extended release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. ER formulations should be swallowed whole. Do not chew or crush. If safety and efficacy of niacin can be effectively monitored, no change in formulation or administration is required after bariatric surgery. Bariatric vitamin supplementation is recommended on a lifelong basis after surgery; consider integration of daily niacin regimen into the bariatric vitamin regimen.</p></div>
<div class="block admp drugH1Div" id="F52613414"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: Administer with food or milk to decrease GI upset; to minimize flushing: Administer dose at bedtime; premedicate with aspirin (adults: 325 mg) 30 minutes before niacin; and avoid alcohol, hot drinks, or spicy food around the time of administration. In adults, may also use other NSAIDs to prevent flushing according to the manufacturer.</p>
<p style="text-indent:-2em;margin-left:2em;">Niaspan: Administer at bedtime with a low-fat snack (do not administer on an empty stomach). Two of the 500 mg and one of the 1,000 mg tablet strengths are interchangeable, but three of the 500 mg and two of the 750 mg tablet strengths are not interchangeable. When switching from immediate-release tablet, initiate Niaspan with the recommended titration schedule. If therapy is interrupted for an extended period, dose should be retitrated.</p>
<p style="text-indent:-2em;margin-left:2em;">Long-acting forms should not be crushed, broken, or chewed. Slo-Niacin may be broken along the score line. Do not substitute long-acting forms for regular/immediate release preparations.</p></div>
<div class="block use drugH1Div" id="F200963"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary supplement:</b> Use as a dietary supplement.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dyslipidemias:</b> Treatment of dyslipidemias (Fredrickson types IIa and IIb or primary hypercholesterolemia) as mono- or adjunctive therapy; to lower the risk of recurrent MI in patients with a history of MI and hyperlipidemia; to slow progression or promote regression of coronary artery disease; adjunctive therapy for severe hypertriglyceridemia in adults at risk of pancreatitis</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Niacin is no longer considered a primary or secondary agent for dyslipidemias. Although niacin consistently affects surrogate markers, especially LDL-C, it has not been shown to reduce cardiovascular disease outcomes beyond that achieved with statin use and may be associated with harm (ACC [Lloyd-Jones 2017]; Garg 2017; Wierzbicki 2014). In two large clinical trials, the addition of niacin to patients receiving simvastatin did not reduce cardiovascular morbidity or mortality (Boden 2011; Landray 2014). May consider use in patients with very high triglyceride levels (&gt;500 mg/dL) or in dyslipidemia for patients who do not achieve the desired response or have intolerance to a statin or other alternative therapy (Boden 2014; Flink 2015).</p></div>
<div class="block off-label drugH1Div" id="F25731058"><span class="drugH1">Use: Off-Label: Adult</span><p>Pellagra</p></div>
<div class="block mst drugH1Div" id="F201016"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues: </span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Niacin may be confused with Minocin, niacinamide, Niaspan </p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299759"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F2914257"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): May enhance the adverse/toxic effect of Niacin. Management: Avoid alcohol around the time of niacin administration to minimize flushing. Use caution in patients who drink larger amounts of alcohol due to the potential for enhanced hepatotoxicity. Consider monitoring serum transaminases more frequently.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: Hyperglycemia-Associated Agents may diminish the therapeutic effect of Antidiabetic Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bile Acid Sequestrants: May decrease the absorption of Niacin. Management: Consider separating the administration times of niacin and bile acid sequestrants by a few hours in order to reduce the potential for decreased efficacy of these agents.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">HMG-CoA Reductase Inhibitors (Statins): Niacin may enhance the adverse/toxic effect of HMG-CoA Reductase Inhibitors (Statins). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rosuvastatin: Niacin may enhance the myopathic (rhabdomyolysis) effect of Rosuvastatin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Simvastatin: Niacin may enhance the myopathic (rhabdomyolysis) effect of Simvastatin. Niacin may increase the serum concentration of Simvastatin.  Management: Avoid this combination in Chinese patients; some non-US labeling state this combination is not recommended in any Asian patients. If coadministered, consider simvastatin dose reductions and monitor closely for signs and symptoms of muscle toxicity.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block pri drugH1Div" id="F5943163"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Water soluble vitamins cross the placenta (IOM 1998).</p>
<p style="text-indent:0em;margin-top:2em;">When used as a dietary supplement, the recommended dietary allowance of niacin is increased during pregnancy compared to nonpregnant patients (IOM 1998).</p>
<p style="text-indent:0em;margin-top:2em;">It is not known if niacin at lipid-lowering doses is harmful to the developing fetus. If a patient becomes pregnant while receiving niacin for primary hypercholesterolemia, niacin should be discontinued. If a patient becomes pregnant while receiving niacin for hypertriglyceridemia, the benefits and risks of continuing niacin should be assessed on an individual basis.</p></div>
<div class="block brc drugH1Div" id="F5943165"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">Niacin is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">Concentrations of niacin in breast milk increase with supplementation. When used as a dietary supplement, the recommended dietary allowance of niacin is increased in breastfeeding patients compared to nonbreastfeeding patients (IOM 1998). Doses of niacin for the treatment of dyslipidemias are greater than those used as a dietary supplement. Due to the potential for serious adverse reactions in the breastfed infant (including hepatoxicity), the manufacturer recommends that breastfeeding be discontinued when niacin is used for treatment of dyslipidemias</p></div>
<div class="block dic drugH1Div" id="F200971"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Should be taken with meal; low-fat meal if treating dyslipidemia. Avoid alcohol, hot or spicy foods/liquids around the time of niacin dose.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary adequate intake</b> (National Academy of Sciences, 1998):</p>
<p style="text-indent:-2em;margin-left:4em;">0 to 5 months: 2 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">6 to 11 months: 3 mg daily</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dietary recommended daily allowances </b>(National Academy of Sciences, 1998):</p>
<p style="text-indent:-2em;margin-left:4em;">1 to 3 years: 6 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">4 to 8 years: 8 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">9 to 13 years: 12 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">14 to 18 years: Females: 14 mg daily; Males: 16 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">≥19 years: Females: 14 mg daily; Males: 16 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">Pregnancy (all ages): 18 mg daily</p>
<p style="text-indent:-2em;margin-left:4em;">Lactation (all ages): 17 mg daily</p></div>
<div class="block mop drugH1Div" id="F200960"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Blood glucose (in diabetic patients); if on concurrent HMG-CoA reductase inhibitor, may periodically check CPK and serum potassium; liver function tests pretreatment, every 6 to 12 weeks for first year, then periodically (approximately every 6 months), monitor liver function more frequently if history of transaminase elevation with prior use; lipid profile; platelets (if on anticoagulants); PT (if on anticoagulants); uric acid (if predisposed to gout); phosphorus (if predisposed to hypophosphatemia)</p></div>
<div class="block pha drugH1Div" id="F200951"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Niacin (nicotinic acid) is bioconverted to nicotinamide which is further converted to nicotinamide adenine dinucleotide (NAD+) and the hydride equivalent (NADH) which are coenzymes necessary for tissue metabolism, lipid metabolism, and glycogenolysis (Belenky 2006; Sauve 2008). The mechanism by which niacin (in lipid-lowering doses) affects plasma lipoproteins is not fully understood. It may involve several actions including partial inhibition of release of free fatty acids from adipose tissue, and increased lipoprotein lipase activity, which may increase the rate of chylomicron triglyceride removal from plasma. Ultimately, niacin reduces total cholesterol, apolipoprotein (apo) B, triglycerides, VLDL, LDL, lipoprotein (a), and increases HDL and other important components and subfractions (eg, LPA-I) (Kamanna 2000)</p></div>
<div class="block phk drugH1Div" id="F200967"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Immediate release formulation: Rapid and extensive. Extent of niacin ER absorption from niacin ER/lovastatin is increased (22% to 30%) with food.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: &lt;20% bound to serum proteins</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Extensive first-pass metabolism; converted to nicotinamide adenine dinucleotide, nicotinuric acid (after conjugation with glycine), and other metabolites. At doses used to treat hyperlipidemia, metabolic pathways are saturable.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Single dose studies indicate that only certain Niaspan tablet strengths are interchangeable (ie, two 500 mg tablets are equivalent to one 1,000 mg tablet; however, three 500 mg tablets are <b>not</b> equivalent to two 750 mg tablets) </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 20 to 48 minutes </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, serum: Immediate release formulation: 30 to 60 minutes; extended release formulation: 4 to 5 hours </p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine 60% to 88% (unchanged drug [up to 12% recovered after multiple dosing] and metabolites) </p></div>
<div class="block phksp drugH1Div" id="F51154895"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Sex: Steady-state plasma concentrations and metabolites are generally higher in women.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F200972"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Niacin</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Niaspan</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Niaspan</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Nicotinic acid dha | Thompson's niacin</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Niaspan</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Acinic | Metri</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Acidum nicotinicum streuli | Niaspan</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Cotina | Niaspan | Niaspan cf | Vectidan</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ben yue | Gao ci ke | Niacin | Niaspan</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Acido Nicotinico Ecar | Niaspan</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Niacin | Niaspan</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Niacin | Niacina | Niaspan</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Acidum nicotinicum | Biocare vitamin b3</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Nicotipan</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Lipolyt | Niaspan</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Niaspan</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Niacin Ifet</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Niaspan | Nicocin</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Acidum nicotinicum</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Niaspan</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Erhdl | Neasyn | Nialip | Niatroy | Nicinal XL</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Motel nicotinate | Nyclin</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Exrip | Locol | Niatin ER</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Niacin | Niaspan | Women's Libido Formula</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Acidum nicotinicum | Peviton</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Niaspan</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Acidum nicotinicum | Enduracin | Niaspan | Peviton</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Hipocol | Nia | Niaspan</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Niaspan</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Niaspan</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Niacin | Niaspan</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Apo-nicotinic acid | B3 Niacin | Niacin-odan | Solgar niacin</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Egol | Niaspan</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Nicosur</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Niacyn | Peviton</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Endur-acin | Niacin | Niacor | Niaspan | Slo-Niacin</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Niaspan</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Acidum nicotinic</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Acidum nicotinicum | Enduracin</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Niaspan</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Natinate | Niacin | Niaspan</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Niascor | Niaspan</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Acidum nicotinicum</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Acido nicotinico | Nicolip | Nilatan</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Niaspan</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Be-tabs nicotinic acid | Niacin</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-17161604">
<a name="17161604"></a>Belenky P, Bogan KL, Brenner C. NAD+ metabolism in health and disease. <i>Trends Biochem Sci</i>. 2006;32(1):12-19.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/17161604/pubmed" id="17161604" target="_blank">17161604</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24363242">
<a name="24363242"></a>Boden WE, Sidhu MS, Toth PP. The therapeutic role of niacin in dyslipidemia management. <i>J Cardiovasc Pharmacol Ther</i>. 2014;19(2):141-158.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/24363242/pubmed" id="24363242" target="_blank">24363242</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8516088">
<a name="8516088"></a>Colletti RB, Neufeld EJ, Roff NK, McAuliffe TL, Baker AL, Newburger JW. Niacin treatment of hypercholesterolemia in children. <i>Pediatrics</i>. 1993;92(1):78-82.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/8516088/pubmed" id="8516088" target="_blank">8516088</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1088963">
<a name="1088963"></a>The Coronary Drug Project Research Group. Clofibrate and Niacin in Coronary Heart Disease. <i>JAMA</i>. 1975;231(4):360-381.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/1088963/pubmed" id="1088963" target="_blank">1088963</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18596007">
<a name="18596007"></a>Daniels SR, Greer FR; American Academy of Pediatrics Committee on Nutrition. Lipid Screening and Cardiovascular Health in Childhood. <i>Pediatrics</i>. 2008;122(1):198-208.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/18596007/pubmed" id="18596007" target="_blank">18596007</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18356638">
<a name="18356638"></a>Delgado-Sanchez L, Godkar D, Niranjan S. Pellagra: rekindling of an old flame. <i>Am J Ther</i>. 2008;15(2):173-175.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/18356638/pubmed" id="18356638" target="_blank">18356638</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin and Choline. Standing Committee on the Scientific Evaluation of Dietary Reference Intakes, Food and Nutrition Board, Institute of Medicine. National Academy of Sciences, Washington, DC: National Academy Press; 1998. <a href="http://www.nap.edu" target="_blank">http://www.nap.edu</a>.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23166211">
<a name="23166211"></a>Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS Guideline for the Diagnosis and Management of Patients With Stable Ischemic Heart Disease: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. <i>Circulation</i>. 2012;126(25):3097-3137.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/23166211/pubmed" id="23166211" target="_blank">23166211</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25690588">
<a name="25690588"></a>Flink L, Underberg JA, Newman JD, Gianos E. The recent national lipid association recommendations: how do they compare to other established dyslipidemia guidelines? <i>Curr Atheroscler Rep</i>. 2015;17(4):494.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/25690588/pubmed" id="25690588" target="_blank">25690588</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27793642">
<a name="27793642"></a>Garg A, Sharma A, Krishnamoorthy P, et al. Role of niacin in current clinical practice: a systematic review. <i>Am J Med</i>. 2017;130(2):173-187.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/27793642/pubmed" id="27793642" target="_blank">27793642</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26370223">
<a name="26370223"></a>Goldie C, Taylor AJ, Nguyen P, et al. Niacin therapy and the risk of new-onset diabetes: a meta-analysis of randomised controlled trials. <i>Heart</i>. 2016;102(3):198-203. doi:10.1136/heartjnl-2015-308055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/26370223/pubmed" id="26370223" target="_blank">26370223</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17368274">
<a name="17368274"></a>Guyton JR, Bays HE. Safety considerations with niacin therapy. <i>Am J Cardiol</i>. 2007;99(6A):22C-31C.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/17368274/pubmed" id="17368274" target="_blank">17368274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-14693013">
<a name="14693013"></a>Hegyi J, Schwartz RA, Hegyi V. Pellagra: Dermatitis, Dementia, and Diarrhea. <i>Int J Dermatol</i>. 2004;43(1):1-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/14693013/pubmed" id="14693013" target="_blank">14693013</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  IOM (Institute of Medicine). <i>Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B</i><sub>6</sub><i>, Folate, Vitamin B</i><sub>12</sub><i>, Pantothenic Acid, Biotin and Choline</i>. National Academy Press, 1998.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21034991">
<a name="21034991"></a>Jen M, Yan AC. Syndromes associated with nutritional deficiency and excess. <i>Clin Dermatol</i>, 2010;28(6):669-685.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/21034991/pubmed" id="21034991" target="_blank">21034991</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11122723">
<a name="11122723"></a>Kamanna VS, Kashyap ML. Mechanism of Action of Niacin on Lipoprotein Metabolism. <i>Curr Atheroscler Rep</i>. 2000;2(1):36-46.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/11122723/pubmed" id="11122723" target="_blank">11122723</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Saunders Elsevier; 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2886926">
<a name="2886926"></a>Lloyd-Jones DM, Morris PB, Ballantyne CM, et al. 2017 focused update of the 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. <i>J Am Coll Cardiol</i>. 2017;70(14):1785-1822. doi:10.1016/j.jacc.2017.07.745<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/2886926/pubmed" id="2886926" target="_blank">2886926</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17377073">
<a name="17377073"></a>McCrindle BW, Urbina EM, Dennison BA, et al. Drug Therapy of High-Risk Lipid Abnormalities in Children and Adolescents: A Scientific Statement from the American Heart Association Atherosclerosis, Hypertension, and Obesity in Youth Committee, Council of Cardiovascular Disease in the Young, With the Council on Cardiovascular Nursing. <i>Circulation</i>. 2007;115(14):1948-1967.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/17377073/pubmed" id="17377073" target="_blank">17377073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26343214">
<a name="26343214"></a>Miller ML, Wright CC, Browne B. Lipid-lowering medications for children and adolescents. <i>J Clin Lipidol</i>. 2015;9(5)(suppl):S67-S76.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/26343214/pubmed" id="26343214" target="_blank">26343214</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  NHLBI. Expert Panel on Integrated Guidelines for Cardiovascular Health and Risk Reduction in Children and Adolescents. <a href="http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf" target="_blank">http://www.nhlbi.nih.gov/guidelines/cvd_ped/peds_guidelines_full.pdf</a>. Published October 2011.</div>
</li>
<li>
<div class="reference">
                  Niacor (niacin) [prescribing information]. Birmingham, AL: Avondale Pharmaceuticals LLC; June 2020.</div>
</li>
<li>
<div class="reference">
                  Niaspan (niacin) extended-release tablet [prescribing information]. North Chicago, IL: AbbVie Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23186222">
<a name="23186222"></a>Oldham MA, Ivkovic A. Pellagrous encephalopathy presenting as alcohol withdrawal delirium: a case series and literature review. <i>Addict Sci Clin Pract</i>, 2012;7:12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/23186222/pubmed" id="23186222" target="_blank">23186222</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12777163">
<a name="12777163"></a>Prousky JE. Pellagra may be a rare secondary complication of anorexia nervosa: a systematic review of the literature. <i>Altern Med Rev</i>. 2003;8(2):180-185.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/12777163/pubmed" id="12777163" target="_blank">12777163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18165311">
<a name="18165311"></a>Sauve AA. NAD+ and vitamin B3: from metabolism to therapies. <i>JPET</i>. 2008;324(3):883-893.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/18165311/pubmed" id="18165311" target="_blank">18165311</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Slo Niacin [prescribing information]. Louisville, KY: MainPointe Pharmaceuticals LLC; June 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24222016">
<a name="24222016"></a>Stone NJ, Robinson JG, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. <i>Circulation</i>. 2014;129(25)(suppl 2):S1-S45.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/24222016/pubmed" id="24222016" target="_blank">24222016</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25318657">
<a name="25318657"></a>Wierzbicki AS, Viljoen A. Fibrates and niacin: is there a place for them in clinical practice? <i>Expert Opin Pharmacother</i>. 2014;15(18):2673-2680.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/25318657/pubmed" id="25318657" target="_blank">25318657</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  World Health Organization. Pellagra and its prevention and control in major emergencies. http://www.who.int/nutrition/publications/emergencies/WHO_NHD_00.10/en/. Published 2000.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27046161">
<a name="27046161"></a>Writing Committee, Lloyd-Jones DM, Morris PB, et al. 2016 ACC expert consensus decision pathway on the role of non-statin therapies for LDL-cholesterol lowering in the management of atherosclerotic cardiovascular disease risk: a report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. <i>J Am Coll Cardiol</i>. 2016;68(1):92-125.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/niacin-vitamin-b3-drug-information/abstract-text/27046161/pubmed" id="27046161" target="_blank">27046161</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 9695 Version 435.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
